Halos engineers a synthetic, scalable version of human fetal plasma, creating the most regenerative biochemical environment for use in cell culture and regenerative medicine research. By producing lab‑grown fetal plasma, the platform provides an ethical alternative to traditional sources, enabling more consistent and controllable experimental conditions. The technology is positioned as a foundational tool for advancing regenerative therapies and biomedical studies.
Funding
Funding not disclosed
Founders
Product
Problem
Researchers lack access to ethically sourced, highly regenerative human fetal plasma, limiting the ability to develop advanced cell culture systems and regenerative medicine therapies.
Solution
Halos creates a synthetic, lab‑grown human fetal plasma that replicates the unique biochemical environment of early human development. The product is produced at scale using engineered bioprocesses, ensuring consistent composition without reliance on donor tissue. By providing an ethically sourced medium, Halos enables more physiologically relevant cell culture and accelerates preclinical research in regenerative medicine. The platform is positioned as a reusable reagent for laboratories seeking to improve the efficacy and reproducibility of their experiments while adhering to strict ethical standards.
Target Audience
Primary customers are academic and industry research labs focused on cell therapy development, tissue engineering, and regenerative medicine studies.
Features
- Fully synthetic human fetal plasma generated through controlled biomanufacturing, eliminating the need for human donors
- Scalable production process delivering consistent batch-to-batch composition
- Comprehensive biochemical profile that mirrors the regenerative factors present in native fetal plasma
- Compatibility with standard cell culture workflows and a wide range of regenerative medicine assays
- Ethically vetted sourcing and manufacturing pipeline meeting rigorous compliance standards